Leflunomide: New antirheumatic drug: Effect on pregnancy outcomes

E. Kozer, M. E. Moretti, G. Koren

Research output: Contribution to journalShort surveypeer-review

3 Scopus citations

Abstract

QUESTION I am treating a 34-year-old woman with rheumatoid arthritis. She began taking the new drug leflunomide (Arava®) 6 months ago and had good clinical response. She is now planning her first pregnancy. What should she do? ANSWER Leflunomide is a new and effective disease-modifying antirheumatic drug. Animal studies have shown an increased rate of malformations and fetal death in various species, but there are no data on pregnancy outcomes in humans treated with leflunomide. Since the drug has a prolonged and unpredictable elimination half-life, it should be stopped during pregnancy. The manufacturer recommends that patients who wish to become pregnant be treated with cholestyramine, which enhances elimination.

Original languageEnglish
Pages (from-to)721-722
Number of pages2
JournalCanadian Family Physician
Volume47
Issue numberAPR.
StatePublished - 2001
Externally publishedYes

Fingerprint

Dive into the research topics of 'Leflunomide: New antirheumatic drug: Effect on pregnancy outcomes'. Together they form a unique fingerprint.

Cite this